BACKGROUND: Several commercial type-specific serologic tests are available for herpes simplex virus type 2 (HSV-2). Poor specificity of some tests has been reported on samples from sub-Saharan Africa. METHODS: To summarize the performance of the tests using samples from sub-Saharan Africa, we conducted a systematic review of publications reporting performance of commercially available HSV-2 tests against a gold standard (Western Blot or monoclonal antibody-blocking EIA). We used random-effects meta-analyses to summarize sensitivity and specificity of the 2 most commonly evaluated tests, Kalon gG2 enzyme-linked immunosorbent assay (ELISA), and Focus HerpeSelect HSV-2 ELISA. RESULTS: We identified 10 eligible articles that included 21 studies of the performance of Focus, and 12 of Kalon. The primary analyses included studies using the manufacturers' cut-offs (index value = 1.1). Focus had high sensitivity (random effects summary estimate 99%, 95% confidence interval [CI]: 99%-100%) but low specificity (69%, 95% CI: 59%-80%). Kalon had sensitivity of 95% (95% CI: 93%-97%) and specificity of 91% (95% CI: 86%-95%). Specificity of Focus was significantly lower (P = 0.002) among HIV-positive (54%, 95% CI: 40%-68%) than HIV-negative individuals (69%, 95% CI: 56%-82%). When the cut-off optical density index was increased above the recommended value of 1.1 to between 2.2 and 3.5, the specificity of Focus increased to 85% (95% CI: 77%-92%). CONCLUSIONS: Sensitivity and specificity of HSV-2 tests used in sub-Saharan Africa vary by setting, and are lower than reported from studies in the United States and Europe. Increasing the cut-off optical density index may improve test performance. Evaluation of test performance in a given setting may help deciding which test is most appropriate.
BACKGROUND: Several commercial type-specific serologic tests are available for herpes simplex virus type 2 (HSV-2). Poor specificity of some tests has been reported on samples from sub-Saharan Africa. METHODS: To summarize the performance of the tests using samples from sub-Saharan Africa, we conducted a systematic review of publications reporting performance of commercially available HSV-2 tests against a gold standard (Western Blot or monoclonal antibody-blocking EIA). We used random-effects meta-analyses to summarize sensitivity and specificity of the 2 most commonly evaluated tests, Kalon gG2 enzyme-linked immunosorbent assay (ELISA), and Focus HerpeSelect HSV-2 ELISA. RESULTS: We identified 10 eligible articles that included 21 studies of the performance of Focus, and 12 of Kalon. The primary analyses included studies using the manufacturers' cut-offs (index value = 1.1). Focus had high sensitivity (random effects summary estimate 99%, 95% confidence interval [CI]: 99%-100%) but low specificity (69%, 95% CI: 59%-80%). Kalon had sensitivity of 95% (95% CI: 93%-97%) and specificity of 91% (95% CI: 86%-95%). Specificity of Focus was significantly lower (P = 0.002) among HIV-positive (54%, 95% CI: 40%-68%) than HIV-negative individuals (69%, 95% CI: 56%-82%). When the cut-off optical density index was increased above the recommended value of 1.1 to between 2.2 and 3.5, the specificity of Focus increased to 85% (95% CI: 77%-92%). CONCLUSIONS: Sensitivity and specificity of HSV-2 tests used in sub-Saharan Africa vary by setting, and are lower than reported from studies in the United States and Europe. Increasing the cut-off optical density index may improve test performance. Evaluation of test performance in a given setting may help deciding which test is most appropriate.
Authors: Darrell H S Tan; Janet M Raboud; Leah Szadkowski; Tae Joon Yi; Brett Shannon; Rupert Kaul; W Conrad Liles; Sharon L Walmsley Journal: AIDS Res Hum Retroviruses Date: 2014-12-17 Impact factor: 2.205
Authors: Marcia M Hobbs; Sophie W Mwanyumba; Winnie K Luseno; Shane Hartman; Carolyn T Halpern; Denise D Hallfors; Hyunsan Cho Journal: Sex Transm Dis Date: 2017-02 Impact factor: 2.830
Authors: Edith Nakku-Joloba; Fred Kambugu; Julius Wasubire; Joshua Kimeze; Robert Salata; Jeffrey M Albert; Alfred Rimm; Christopher Whalen Journal: Afr Health Sci Date: 2014-12 Impact factor: 0.927
Authors: Supriya D Mehta; Stephen Moses; Corette B Parker; Kawango Agot; Ian Maclean; Robert C Bailey Journal: AIDS Date: 2012-06-01 Impact factor: 4.177
Authors: Denise Dion Hallfors; Hyunsan Cho; Isabella I Mbai; Benson W Millimo; Carolyne Atieno; David Okumu; Winnie K Luseno; Shane Hartman; Carolyn T Halpern; Marcia M Hobbs Journal: Sex Transm Infect Date: 2015-07-02 Impact factor: 3.519
Authors: Christopher R Sudfeld; Paul C Hewett; Nadia N Abuelezam; Satvika Chalasani; Erica Soler-Hampejsek; Christine A Kelly; Barbara S Mensch Journal: Sex Transm Infect Date: 2013-06-21 Impact factor: 3.519
Authors: Marie C D Stoner; Jessie K Edwards; William C Miller; Allison E Aiello; Carolyn T Halpern; Aimée Julien; Amanda Selin; James P Hughes; Jing Wang; Francesc Xavier Gomez-Olive; Ryan G Wagner; Catherine MacPhail; Kathleen Kahn; Audrey Pettifor Journal: J Acquir Immune Defic Syndr Date: 2017-12-15 Impact factor: 3.731